Table 4.

The treatment-related adverse events in the 48 patients with unresectable hepatocellular carcinoma who received atezolizumab plus bevacizumab.

Adverse Event	Any Grades	Grade 3/4
Hypertension	11 (22.9%)	3 (6.3%)
Fatigue	12 (25.0%)	0
Proteinuria	17 (35.4%)	2 (4.2%)
Aspartate/Alanine aminotransferase increase (baseline)	34 (70.8%)	3 (6.3%)
Aspartate/Alanine aminotransferase increase (after lenvatinib)	41 (85.4%)	10 (20.8%)
Diarrhea	3 (6.3%)	1 (2.0%)
Decreased appetite	11 (22.9%)	0
Skin rash	10 (20.8%)	0
Abdominal pain	9 (18.8%)	0
Nausea	7 (14.6%)	0
Palmar-Plantar erythrodysesthesia	3 (6.3%)	0
Bleeding	4 (8.3%)	0